TY - JOUR
T1 - Treatment With Voriconazole in 3 Eyes With Resistant Acanthamoeba Keratitis
AU - Bang, Stacy
AU - Edell, Erica
AU - Eghrari, Allen O.
AU - Gottsch, John D.
N1 - Funding Information:
This study was supported by National Eye Institute, Bethesda, Maryland, Grant No. R01EY016835. The authors indicate no financial conflict of interest. Involved in design and conduct of study (S.B., E.E., J.D.G.); collection, management, analysis, and interpretation of data (S.B., E.E., A.O.E., J.D.G.); and preparation, review, or approval of the manuscript (S.B., E.E., A.O.E., J.D.G.). The study was in accordance with the Declaration of Helsinki, federal and state laws, and Health Insurance Portability and Accountability Act regulations.
Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2010/1
Y1 - 2010/1
N2 - Purpose: To report the use of topical voriconazole 1% (Vfend; Pfizer Inc, New York, New York, USA) ophthalmic solution for Acanthamoeba keratitis (AK) resistant to treatment with chlorhexidine (PerioChip; Dexel Pharma Technologies, Jerusalem, Israel). Design: Retrospective case series. Methods: Three eyes of 2 patients with culture-proven AK were treated at a tertiary care institution, and their charts were reviewed. Topical voriconazole 1% was instituted as second-line treatment for AK unresponsive to standard treatment with chlorhexidine and hexamidine. Treatment with voriconazole 1% was started at 1-hour intervals. Improvement was assessed and defined by absence of clinical signs of active infection and visual improvement. Results: One patient with unilateral AK and 1 patient with bilateral AK who remained culture-positive for Acanthamoeba despite ongoing treatment with chlorhexidine and hexamidine were treated with voriconazole 1% topical solution as an adjuvant. Both patients were contact lens wearers. Of 3 eyes additionally treated with voriconazole, 2 eyes had clinical resolution of disease. One eye demonstrated recurrent disease after penetrating keratoplasty that resolved after intrastromal injection of voriconazole. Conclusions: We report the use of topical and intrastromal voriconazole in successfully treating AK in cases of chlorhexidine- and hexamidine-resistant Acanthamoeba. Voriconazole may be a promising adjuvant agent in treating AK.
AB - Purpose: To report the use of topical voriconazole 1% (Vfend; Pfizer Inc, New York, New York, USA) ophthalmic solution for Acanthamoeba keratitis (AK) resistant to treatment with chlorhexidine (PerioChip; Dexel Pharma Technologies, Jerusalem, Israel). Design: Retrospective case series. Methods: Three eyes of 2 patients with culture-proven AK were treated at a tertiary care institution, and their charts were reviewed. Topical voriconazole 1% was instituted as second-line treatment for AK unresponsive to standard treatment with chlorhexidine and hexamidine. Treatment with voriconazole 1% was started at 1-hour intervals. Improvement was assessed and defined by absence of clinical signs of active infection and visual improvement. Results: One patient with unilateral AK and 1 patient with bilateral AK who remained culture-positive for Acanthamoeba despite ongoing treatment with chlorhexidine and hexamidine were treated with voriconazole 1% topical solution as an adjuvant. Both patients were contact lens wearers. Of 3 eyes additionally treated with voriconazole, 2 eyes had clinical resolution of disease. One eye demonstrated recurrent disease after penetrating keratoplasty that resolved after intrastromal injection of voriconazole. Conclusions: We report the use of topical and intrastromal voriconazole in successfully treating AK in cases of chlorhexidine- and hexamidine-resistant Acanthamoeba. Voriconazole may be a promising adjuvant agent in treating AK.
UR - http://www.scopus.com/inward/record.url?scp=72049109945&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=72049109945&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2009.08.004
DO - 10.1016/j.ajo.2009.08.004
M3 - Article
C2 - 19875089
AN - SCOPUS:72049109945
SN - 0002-9394
VL - 149
SP - 66
EP - 69
JO - American journal of ophthalmology
JF - American journal of ophthalmology
IS - 1
ER -